menu
    • menu

    Find Toremifene Citrate manufacturers, exporters & distributors on PharmaCompass

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Aurigene is a global leader in accelerating drug innovation through discovery, development & manufacturing.

    Virtual Booth

    Contact Supplier

    Midas Pharma provides expertise in developing and supplying APIs, finished products, and intermediates.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-01-06

    Virtual Booth

    Contact Supplier

    ACTIVE PHARMA INGREDIENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass

    Synopsis

    Product SearchProduct Search

    Synopsis

    ACTIVE PHARMA INGREDIENTS

    8

    API Suppliers

    API Suppliers

    6

    USDMF

    US DMFs Filed

    0

    CEP/COS

    CEP/COS Certifications

    2

    JDMF

    JDMFs Filed

    1

    EU WC

    EU WC

    0

    KDMF

    KDMF

    4

    NDC API

    NDC API

    0

    VMF

    NDC API

    5

    Listed Suppliers

    Other Suppliers

    API REF. PRICE (USD/KG)

    $
    $ 0

    MARKET PLACE

    0

    API

    0

    FDF

    0INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    10

    FDF Dossiers

    FDF Dossiers

    3

    FDA Orange Book

    FDA (Orange Book)

    4

    Europe

    Europe

    0

    Canada

    Canada

    2

    Australia

    Australia

    1

    South Africa

    South Africa

    0

    Listed Dossiers

    Listed Dossiers

    0 DRUGS IN DEVELOPMENT

    FDF Dossiers

    DRUG PRODUCT COMPOSITIONS

    REF. STANDARDS OR IMPURITIES

    0

    EDQM

    0

    USP

    0

    JP

    2

    Others

    PATENTS & EXCLUSIVITIES

    0

    US Patents

    0

    US Exclusivities

    1

    Health Canada Patents

    DIGITAL CONTENT

    0

    Data Compilation #PharmaFlow

    0

    Stock Recap #PipelineProspector

    0

    Weekly News Recap #Phispers

    3

    News #PharmaBuzz

    GLOBAL SALES INFORMATION

    US Medicaid

    1,342,469

    Annual Reports

    10

    Finished Drug Prices

    Listed Dossiers

    107 RELATED EXCIPIENT COMPANIES

    179EXCIPIENTS BY APPLICATIONS

    Chemistry

    Click the arrow to open the dropdown
    read-moreClick the button for full data set
    read-moreClick the button for full data set
    Also known as: 89778-27-8, Fareston, Toremifene citrate [usan], Toremifene (citrate), Fc 1157a, Nk 622
    Molecular Formula
    C32H36ClNO8
    Molecular Weight
    598.1  g/mol
    InChI Key
    IWEQQRMGNVVKQW-OQKDUQJOSA-N
    FDA UNII
    2498Y783QT
    Toremifene Citrate
    A first generation selective estrogen receptor modulator (SERM). Like TAMOXIFEN, it is an estrogen agonist for bone tissue and cholesterol metabolism but is antagonistic on mammary and uterine tissue.
    1 2D Structure

    Toremifene Citrate

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    2-[4-[(Z)-4-chloro-1,2-diphenylbut-1-enyl]phenoxy]-N,N-dimethylethanamine;2-hydroxypropane-1,2,3-tricarboxylic acid
    2.1.2 InChI
    InChI=1S/C26H28ClNO.C6H8O7/c1-28(2)19-20-29-24-15-13-23(14-16-24)26(22-11-7-4-8-12-22)25(17-18-27)21-9-5-3-6-10-21;7-3(8)1-6(13,5(11)12)2-4(9)10/h3-16H,17-20H2,1-2H3;13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)/b26-25-;
    2.1.3 InChI Key
    IWEQQRMGNVVKQW-OQKDUQJOSA-N
    2.1.4 Canonical SMILES
    CN(C)CCOC1=CC=C(C=C1)C(=C(CCCl)C2=CC=CC=C2)C3=CC=CC=C3.C(C(=O)O)C(CC(=O)O)(C(=O)O)O
    2.1.5 Isomeric SMILES
    CN(C)CCOC1=CC=C(C=C1)/C(=C(/CCCl)\C2=CC=CC=C2)/C3=CC=CC=C3.C(C(=O)O)C(CC(=O)O)(C(=O)O)O
    2.2 Other Identifiers
    2.2.1 UNII
    2498Y783QT
    2.3 Synonyms
    2.3.1 MeSH Synonyms

    1. Citrate, Toremifene

    2. Fareston

    3. Fc 1157a

    4. Fc-1157a

    5. Fc1157a

    6. Toremifene

    7. Toremifene Citrate (1:1)

    8. Toremifene, (e)-isomer

    2.3.2 Depositor-Supplied Synonyms

    1. 89778-27-8

    2. Fareston

    3. Toremifene Citrate [usan]

    4. Toremifene (citrate)

    5. Fc 1157a

    6. Nk 622

    7. Nsc 613680

    8. Fc-1157a

    9. 89778-27-8 (citrate)

    10. Nsc-613680

    11. Nsc613680

    12. 2-(p-((z)-4-chloro-1,2-diphenyl-1-butenyl)phenoxy)-n,n-dimethylethylamine Citrate (1:1)

    13. 2498y783qt

    14. Toremifene Citrate (fareston, Acapodene)

    15. Dsstox_cid_1367

    16. Dsstox_rid_76113

    17. Dsstox_gsid_21367

    18. (z)-2-(4-(4-chloro-1,2-diphenylbut-1-en-1-yl)phenoxy)-n,n-dimethylethan-1-amine 2-hydroxypropane-1,2,3-tricarboxylate

    19. Ethanamine, 2-(4-(4-chloro-1,2-diphenyl-1-butenyl)phenoxy)-n,n-dimethyl-, (z)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1)

    20. (2-{4-[(1z)-4-chloro-1,2-diphenylbut-1-en-1-yl]phenoxy}ethyl)dimethylamine; 2-hydroxypropane-1,2,3-tricarboxylic Acid

    21. 2-({4-[(1z)-4-chloro-1,2-diphenylbut-1-en-1-yl]phenyl}oxy)-n,n-dimethylethanamine 2-hydroxypropane-1,2,3-tricarboxylate (salt)

    22. Cas-89778-27-8

    23. Ccris 6719

    24. Unii-2498y783qt

    25. 2-[p-[(z)-4-chloro-1,2-diphenyl-1-butenyl]phenoxy]-n,n-dimethylethylamine Citrate (1:1)

    26. Cpd000469213

    27. Schembl4564

    28. (z)-4-chloro-1,2-diphenyl-1-(4-(2-(n,n-dimethylamino)ethoxy)phenyl)-1-butene Citrate (1:1)

    29. Mls001306432

    30. Mls006011608

    31. Chebi:9636

    32. Toremifene Citrate [mi]

    33. Chembl1200675

    34. Dtxsid2021367

    35. Toremifene Citrate (jan/usan)

    36. Toremifene Citrate [jan]

    37. Hms2052c03

    38. Hms2230p09

    39. Hms3264l11

    40. Pharmakon1600-01505682

    41. Toremifene Citrate [vandf]

    42. Toremifene Citrate [mart.]

    43. Hy-b0005

    44. Toremifene Citrate [who-dd]

    45. Tox21_111877

    46. Tox21_301740

    47. Mfcd01729016

    48. Nsc759190

    49. S1776

    50. Akos015888270

    51. Ac-1985

    52. Ccg-101072

    53. Cs-1272

    54. Ks-5242

    55. Nc00322

    56. Nsc-759190

    57. 2-[4-[(z)-4-chloro-1,2-diphenyl-but-1-enyl]phenoxy]-n,n-dimethyl-ethanamine; Citric Acid

    58. Toremifene Citrate [orange Book]

    59. Ncgc00255310-01

    60. 2-[4-[(z)-4-chloro-1,2-diphenylbut-1-enyl]phenoxy]-n,n-dimethylethanamine; 2-hydroxypropane-1,2,3-tricarboxylic Acid

    61. Smr004703372

    62. Toremifene Citrate Salt, >=98% (hplc)

    63. Sw197702-3

    64. T2832

    65. D00967

    66. 778t267

    67. A843307

    68. Sr-01000763502-3

    69. Q27253831

    70. 2-[p-[(z)-4-chloro-1,n- Dimethylethylamine Citrate (1:1)

    71. (z)-2-[4-(4-chloro-1,2-diphenyl-1-butenyl)phenoxy]-n,n-dimethylethanamine Citrate

    72. (z)-2-[4-(4-chloro-1,n- Dimethylethanamine, 2-hydroxy-1,2,3-propanetricarboxylate (1:1)

    73. (z)-4-chloro-1-(4-dimethylaminoethoxyphenyl)-1,2-diphenyl-1-butene Citrate

    74. (z)-2-(4-(4-chloro-1,2-diphenylbut-1-en-1-yl)phenoxy)-n,n-dimethylethanamine 2-hydroxypropane-1,2,3-tricarboxylate

    75. (z)-2-(4-(4-chloro-1,2-diphenylbut-1-enyl)phenoxy)-n,n-dimethylethanamine 2-hydroxypropane-1,2,3-tricarboxylate

    76. 2-[4-[(z)-4-chloranyl-1,2-diphenyl-but-1-enyl]phenoxy]-n,n-dimethyl-ethanamine; 2-oxidanylpropane-1,2,3-tricarboxylic Acid

    2.4 Create Date
    2005-03-26
    3 Chemical and Physical Properties
    Molecular Weight 598.1 g/mol
    Molecular Formula C32H36ClNO8
    Hydrogen Bond Donor Count4
    Hydrogen Bond Acceptor Count9
    Rotatable Bond Count14
    Exact Mass597.2129448 g/mol
    Monoisotopic Mass597.2129448 g/mol
    Topological Polar Surface Area145 Ų
    Heavy Atom Count42
    Formal Charge0
    Complexity710
    Isotope Atom Count0
    Defined Atom Stereocenter Count0
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count1
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count2
    4 Drug and Medication Information
    4.1 Drug Indication

    First line hormone treatment of hormone-dependent metastatic breast cancer in postmenopausal patients.

    Fareston is not recommended for patients with estrogen receptor negative tumours.

    5 Pharmacology and Biochemistry
    5.1 MeSH Pharmacological Classification

    Antineoplastic Agents, Hormonal

    Antineoplastic agents that are used to treat hormone-sensitive tumors. Hormone-sensitive tumors may be hormone-dependent, hormone-responsive, or both. A hormone-dependent tumor regresses on removal of the hormonal stimulus, by surgery or pharmacological block. Hormone-responsive tumors may regress when pharmacologic amounts of hormones are administered regardless of whether previous signs of hormone sensitivity were observed. The major hormone-responsive cancers include carcinomas of the breast, prostate, and endometrium; lymphomas; and certain leukemias. (From AMA Drug Evaluations Annual 1994, p2079) (See all compounds classified as Antineoplastic Agents, Hormonal.)

    Bone Density Conservation Agents

    Agents that inhibit BONE RESORPTION and/or favor BONE MINERALIZATION and BONE REGENERATION. They are used to heal BONE FRACTURES and to treat METABOLIC BONE DISEASES such as OSTEOPOROSIS. (See all compounds classified as Bone Density Conservation Agents.)

    Selective Estrogen Receptor Modulators

    A structurally diverse group of compounds distinguished from ESTROGENS by their ability to bind and activate ESTROGEN RECEPTORS but act as either an agonist or antagonist depending on the tissue type and hormonal milieu. They are classified as either first generation because they demonstrate estrogen agonist properties in the ENDOMETRIUM or second generation based on their patterns of tissue specificity. (Horm Res 1997;48:155-63) (See all compounds classified as Selective Estrogen Receptor Modulators.)

    5.2 FDA Pharmacological Classification
    5.2.1 Pharmacological Classes
    Selective Estrogen Receptor Modulators [MoA]; Estrogen Agonist/Antagonist [EPC]
    5.3 ATC Code

    L02BA02

    Related Excipient Companies

    Upload your portfolio for free, ask us

    Excipients by Applications

    Click here to find the perfect excipient manufacturers by their capabilities

    Fillers, Diluents & Binders

    read-more
    read-more

    Direct Compression

    read-more
    read-more

    Disintegrants & Superdisintegrants

    read-more
    read-more

    Thickeners and Stabilizers

    read-more
    read-more

    Granulation

    read-more
    read-more

    Co-Processed Excipients

    read-more
    read-more

    Lubricants & Glidants

    read-more
    read-more

    Controlled & Modified Release

    read-more
    read-more

    Solubilizers

    read-more
    read-more

    Taste Masking

    read-more
    read-more

    Chewable & Orodispersible Aids

    read-more
    read-more

    Coating Systems & Additives

    read-more
    read-more

    Emulsifying Agents

    read-more
    read-more

    Parenteral

    read-more
    read-more

    Film Formers & Plasticizers

    read-more
    read-more

    API Stability Enhancers

    read-more
    read-more

    Rheology Modifiers

    read-more
    read-more

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more

    Global Sales Information

    Do you need Business Intel? Ask us

    Patents & EXCLUSIVITIES

    Check the patents & exclusivity for this product

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ANALYTICAL

    Upload your methods for free, ask us

    ABOUT THIS PAGE

    Toremifene Citrate Manufacturers

    A Toremifene Citrate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Toremifene Citrate, including repackagers and relabelers. The FDA regulates Toremifene Citrate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Toremifene Citrate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

    click here to find a list of Toremifene Citrate manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.

    Toremifene Citrate Suppliers

    A Toremifene Citrate supplier is an individual or a company that provides Toremifene Citrate active pharmaceutical ingredient (API) or Toremifene Citrate finished formulations upon request. The Toremifene Citrate suppliers may include Toremifene Citrate API manufacturers, exporters, distributors and traders.

    click here to find a list of Toremifene Citrate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

    Toremifene Citrate USDMF

    A Toremifene Citrate DMF (Drug Master File) is a document detailing the whole manufacturing process of Toremifene Citrate active pharmaceutical ingredient (API) in detail. Different forms of Toremifene Citrate DMFs exist exist since differing nations have different regulations, such as Toremifene Citrate USDMF, ASMF (EDMF), JDMF, CDMF, etc.

    A Toremifene Citrate DMF submitted to regulatory agencies in the US is known as a USDMF. Toremifene Citrate USDMF includes data on Toremifene Citrate's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Toremifene Citrate USDMF is kept confidential to protect the manufacturer’s intellectual property.

    click here to find a list of Toremifene Citrate suppliers with USDMF on PharmaCompass.

    Toremifene Citrate JDMF

    The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.

    The Toremifene Citrate Drug Master File in Japan (Toremifene Citrate JDMF) empowers Toremifene Citrate API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).

    PMDA reviews the Toremifene Citrate JDMF during the approval evaluation for pharmaceutical products. At the time of Toremifene Citrate JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.

    click here to find a list of Toremifene Citrate suppliers with JDMF on PharmaCompass.

    Toremifene Citrate WC

    A Toremifene Citrate written confirmation (Toremifene Citrate WC) is an official document issued by a regulatory agency to a Toremifene Citrate manufacturer, verifying that the manufacturing facility of a Toremifene Citrate active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Toremifene Citrate APIs or Toremifene Citrate finished pharmaceutical products to another nation, regulatory agencies frequently require a Toremifene Citrate WC (written confirmation) as part of the regulatory process.

    click here to find a list of Toremifene Citrate suppliers with Written Confirmation (WC) on PharmaCompass.

    Toremifene Citrate NDC

    National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Toremifene Citrate as an active pharmaceutical ingredient (API).

    Finished drug products

    The FDA updates the NDC directory daily. The NDC numbers for Toremifene Citrate API and other APIs are published in this directory by the FDA.

    Unfinished drugs

    The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

    Pharmaceutical companies that manufacture Toremifene Citrate as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

    Compounded drug products

    The NDC directory also contains data on finished compounded human drug products that contain Toremifene Citrate and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Toremifene Citrate NDC to their finished compounded human drug products, they may choose to do so.

    click here to find a list of Toremifene Citrate suppliers with NDC on PharmaCompass.

    Toremifene Citrate GMP

    Toremifene Citrate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

    GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

    PharmaCompass offers a list of Toremifene Citrate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Toremifene Citrate GMP manufacturer or Toremifene Citrate GMP API supplier for your needs.

    Toremifene Citrate CoA

    A Toremifene Citrate CoA (Certificate of Analysis) is a formal document that attests to Toremifene Citrate's compliance with Toremifene Citrate specifications and serves as a tool for batch-level quality control.

    Toremifene Citrate CoA mostly includes findings from lab analyses of a specific batch. For each Toremifene Citrate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

    Toremifene Citrate may be tested according to a variety of international standards, such as European Pharmacopoeia (Toremifene Citrate EP), Toremifene Citrate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Toremifene Citrate USP).

    Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
    For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search